163 related articles for article (PubMed ID: 30395538)
1. Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation.
Clocchiatti A; Ghosh S; Procopio MG; Mazzeo L; Bordignon P; Ostano P; Goruppi S; Bottoni G; Katarkar A; Levesque M; Kölblinger P; Dummer R; Neel V; Özdemir BC; Dotto GP
J Clin Invest; 2018 Dec; 128(12):5531-5548. PubMed ID: 30395538
[TBL] [Abstract][Full Text] [Related]
2. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation.
Procopio MG; Laszlo C; Al Labban D; Kim DE; Bordignon P; Jo SH; Goruppi S; Menietti E; Ostano P; Ala U; Provero P; Hoetzenecker W; Neel V; Kilarski WW; Swartz MA; Brisken C; Lefort K; Dotto GP
Nat Cell Biol; 2015 Sep; 17(9):1193-204. PubMed ID: 26302407
[TBL] [Abstract][Full Text] [Related]
3. ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation.
Mazzeo L; Ghosh S; Di Cicco E; Isma J; Tavernari D; Samarkina A; Ostano P; Youssef MK; Simon C; Dotto GP
Nat Commun; 2024 Feb; 15(1):1038. PubMed ID: 38310103
[TBL] [Abstract][Full Text] [Related]
4. PDCD4 is a CSL associated protein with a transcription repressive function in cancer associated fibroblast activation.
Jo SH; Kim DE; Clocchiatti A; Dotto GP
Oncotarget; 2016 Sep; 7(37):58717-58727. PubMed ID: 27542230
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells.
Liao CP; Chen LY; Luethy A; Kim Y; Kani K; MacLeod AR; Gross ME
Endocr Relat Cancer; 2017 Apr; 24(4):157-170. PubMed ID: 28264911
[TBL] [Abstract][Full Text] [Related]
6. Dualism of FGF and TGF-β Signaling in Heterogeneous Cancer-Associated Fibroblast Activation with ETV1 as a Critical Determinant.
Bordignon P; Bottoni G; Xu X; Popescu AS; Truan Z; Guenova E; Kofler L; Jafari P; Ostano P; Röcken M; Neel V; Dotto GP
Cell Rep; 2019 Aug; 28(9):2358-2372.e6. PubMed ID: 31461652
[TBL] [Abstract][Full Text] [Related]
7. Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.
Cioni B; Nevedomskaya E; Melis MHM; van Burgsteden J; Stelloo S; Hodel E; Spinozzi D; de Jong J; van der Poel H; de Boer JP; Wessels LFA; Zwart W; Bergman AM
Mol Oncol; 2018 Aug; 12(8):1308-1323. PubMed ID: 29808619
[TBL] [Abstract][Full Text] [Related]
8. The ULK3 Kinase Is Critical for Convergent Control of Cancer-Associated Fibroblast Activation by CSL and GLI.
Goruppi S; Procopio MG; Jo S; Clocchiatti A; Neel V; Dotto GP
Cell Rep; 2017 Sep; 20(10):2468-2479. PubMed ID: 28877478
[TBL] [Abstract][Full Text] [Related]
9. Convergent roles of ATF3 and CSL in chromatin control of cancer-associated fibroblast activation.
Kim DE; Procopio MG; Ghosh S; Jo SH; Goruppi S; Magliozzi F; Bordignon P; Neel V; Angelino P; Dotto GP
J Exp Med; 2017 Aug; 214(8):2349-2368. PubMed ID: 28684431
[TBL] [Abstract][Full Text] [Related]
10. A role for stromal autophagy in cancer-associated fibroblast activation.
Goruppi S; Clocchiatti A; Dotto GP
Autophagy; 2019 Apr; 15(4):738-739. PubMed ID: 30653445
[TBL] [Abstract][Full Text] [Related]
11. Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B.
Al Labban D; Jo SH; Ostano P; Saglietti C; Bongiovanni M; Panizzon R; Dotto GP
J Clin Invest; 2018 Jun; 128(6):2581-2599. PubMed ID: 29757189
[TBL] [Abstract][Full Text] [Related]
12. CSL controls telomere maintenance and genome stability in human dermal fibroblasts.
Bottoni G; Katarkar A; Tassone B; Ghosh S; Clocchiatti A; Goruppi S; Bordignon P; Jafari P; Tordini F; Lunardi T; Hoetzenecker W; Neel V; Lingner J; Paolo Dotto G
Nat Commun; 2019 Aug; 10(1):3884. PubMed ID: 31467287
[TBL] [Abstract][Full Text] [Related]
13. Nuclear lamin A/C phosphorylation by loss of Androgen Receptor is a global determinant of cancer-associated fibroblast activation.
Ghosh S; Isma J; Mazzeo L; Toniolo A; Simon C; Dotto GP
bioRxiv; 2023 Jun; ():. PubMed ID: 37425957
[TBL] [Abstract][Full Text] [Related]
14. NOTCH1 gene amplification promotes expansion of Cancer Associated Fibroblast populations in human skin.
Katarkar A; Bottoni G; Clocchiatti A; Goruppi S; Bordignon P; Lazzaroni F; Gregnanin I; Ostano P; Neel V; Dotto GP
Nat Commun; 2020 Oct; 11(1):5126. PubMed ID: 33046701
[TBL] [Abstract][Full Text] [Related]
15. TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells.
Kikuchi M; Okumura F; Tsukiyama T; Watanabe M; Miyajima N; Tanaka J; Imamura M; Hatakeyama S
Biochim Biophys Acta; 2009 Dec; 1793(12):1828-36. PubMed ID: 19909775
[TBL] [Abstract][Full Text] [Related]
16. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
[TBL] [Abstract][Full Text] [Related]
17. Targeting nuclear receptors in cancer-associated fibroblasts as concurrent therapy to inhibit development of chemoresistant tumors.
Chan JSK; Sng MK; Teo ZQ; Chong HC; Twang JS; Tan NS
Oncogene; 2018 Jan; 37(2):160-173. PubMed ID: 28892046
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide analysis of AR binding and comparison with transcript expression in primary human fetal prostate fibroblasts and cancer associated fibroblasts.
Nash C; Boufaied N; Mills IG; Franco OE; Hayward SW; Thomson AA
Mol Cell Endocrinol; 2018 Aug; 471():1-14. PubMed ID: 28483704
[TBL] [Abstract][Full Text] [Related]
19. Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.
Sorrentino C; Miele L; Porta A; Pinto A; Morello S
Oncotarget; 2016 Sep; 7(39):64274-64288. PubMed ID: 27590504
[TBL] [Abstract][Full Text] [Related]
20. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
